Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia

Table 1 Characteristics of the patients with schizophrenia (n = 3306)

Variates	mean ± SD
Sex (male), n (%)	1342 (40.6)
Age (years)	34.5 ± 14.18
Height (cm)	165.6 ± 7.66
Weight (kg)	64.5 ± 12.44
Duration of illness (month)	89.1 ± 111.09
Baseline BPRS total score	48.8 ± 15.03
Baseline BPRS factor scores
Anxiety/depression	9.8 ± 4.11
Anergia	10.2 ± 3.69
Thought disturbance	12.1 ± 4.30
Activation	6.7 ± 3.26
Hostility/suspiciousness	10.0 ± 3.89

BPRS: Brief psychiatric rating scale.

Table 2 Brief psychiatric rating scale: Total score and 5-factor model scores from the baseline to 12 weeks after initiation of blonanserin treatment (mean ± SD)

BPRS	Baseline (n = 3306)	2-4 weeks (n = 3188)	6-8 weeks (n = 2957)	12 weeks (n = 2775)	F value	P value
Total score	48.8 ± 15.03	38.5 ± 13.32	32.3 ± 11.78	27.7 ± 10.08	1574	< 0.001
Anxiety/depression	9.8 ± 4.11	8.2 ± 3.46	7.1 ± 3.07	6.2 ± 2.67	638.5	< 0.001
Anergia	10.2 ± 3.69	8.4 ± 3.14	7.2 ± 2.74	6.3 ± 2.38	898.3	< 0.001
Thought disturbance	12.1 ± 4.30	9.4 ± 3.80	7.6 ± 3.33	6.4 ± 2.85	1410	< 0.001
Activation	6.7 ± 3.26	5.3 ± 2.61	4.5 ± 2.17	4.0 ± 1.74	695.5	< 0.001
Hostility/suspiciousness	10.0 ± 3.89	7.3 ± 3.17	5.8 ± 2.63	4.8 ± 2.16	1700	< 0.001

BPRS: Brief psychiatric rating scale.

Table 3 Major adverse drug reactions involving systematic and clinical manifestations

ADRs	Mild patients, n (%)	Mild cases	Moderate patients, n (%)	Moderate cases	Severe patients, n (%)	Severe cases
Total ADRs	443 (13.4)	656	164 (5.0)	219	15 (0.5)	16
Neurological disorders	352 (10.6)	420	127 (3.8)	159	7 (0.2)	8
Akathisia	170 (5.1)	174	66 (2.0)	68	4 (0.1)	4
Tremor	97 (2.9)	100	27 (0.8)	27	0 (0)	0
Dystonia	54 (1.6)	54	23 (0.7)	24	2 (0.1)	2
Parkinsonism	43 (1.3)	44	22 (0.7)	22	1 (0.0)	1
Investigations	74 (2.2)	85	23 (0.7)	25	3 (0.1)	3
Elevated transaminase level	6 (0.2)	6	0 (0)	0	0 (0)	0
Weight gain	34 (1.0)	34	5 (0.2)	5	0 (0)	0
Increased blood prolactin	20 (0.6)	20	12 (0.4)	12	1 (0.0)	1
Increased blood glucose	2 (0.1)	2	1 (0.0)	1	1 (0.0)	1
Decreased white blood cell count	2 (0.1)	2	1 (0.0)	1	0 (0)	0
Prolonged electrocardiogram QT	2 (0.1)	2	0 (0)	0	1 (0.0)	1
Gastrointestinal disorders	48 (1.5)	50	11 (0.3)	11	0 (0)	0
Eye disorders	8 (0.2)	10	1 (0.0)	1	0 (0)	0
Psychiatric disorders	16 (0.5)	18	4 (0.1)	5	0 (0)	0
Kidney and urinary disorders	2 (0.1)	2	4 (0.1)	4	1 (0.0)	1

ADR: Adverse drug reactions.

Table 4 Multivariate analysis of the influencing factors of brief psychiatric rating scale score reduction in general population

Characteristic	β	95%CI	P value
Current episode duration (month)	-0.03	-0.05 to -0.01	< 0.001
Whether in acute phase
No	0.00	N/A	N/A
Yes	5.42	4.0 to 6.9	< 0.001
Previous episodes	-0.22	-0.41 to -0.03	0.024
Baseline BPRS score	0.51	0.47 to 0.56	< 0.001
Mean daily dose of concomitant anti-psychiatrics1	-0.01	-0.01 to 0.00	< 0.001
Number of types of sedative-hypnotic agents	-1.22	-2.00 to -0.44	0.002

¹Chlorpromazine equivalent dose.

CI: Confidence interval; BPRS: Brief psychiatric rating scale; N/A: Not applicable.

Table 5 Multivariate analysis of the influencing factors of brief psychiatric rating scale: Score reduction in non-acute phase patients with prominent negative symptoms at baseline

Characteristic	β	95%CI	P value
Baseline blunted affect score	N/A	N/A	0.061
≤ 3	0.00	N/A	N/A
≥ 4	2.45	-0.12 to 5.01	N/A
Disease duration (months)	-0.02	-0.04 to 0.01	0.217
Previous onset	-0.38	-0.63 to -0.13	0.003
Mean daily dose of concomitant anti-psychiatrics1	-0.01	-0.01 to 0.00	0.011
Baseline BPRS score	0.34	0.27 to 0.41	< 0.001
Number of types of sedative-hypnotic agents	-2.53	-4.17 to -0.90	0.003

¹Chlorpromazine equivalent dose.

CI: Confidence interval; BPRS: Brief psychiatric rating scale; N/A: Not applicable.